Key Takeaways
Cardinal Health (CAH) shares fell 7 percent Thursday even after the company raised its full-year earnings guidance for the second consecutive quarter.
The company's quarterly profit declined to $399 million from $506 million a year earlier, which management attributed to a $184 million pretax goodwill impairment charge.
For the third quarter, the pharmaceutical distributor reported adjusted earnings of $3.17 a share, easily beating Wall Street's forecast of $2.79. However, revenue climbed 11 percent to $60.9 billion, missing the consensus call for $62.1 billion.
The stock became one of the S&P 500's worst performers as the revenue miss and impairment charge overshadowed the higher outlook, signaling investor concern over the quality of the earnings beat.
Performance was mixed across the company's business units. The Pharmaceutical and Specialty Solutions division saw revenue increase 11 percent to $56.1 billion. In contrast, the Global Medical Products and Distribution segment reported revenue that was roughly flat compared to the prior year, citing lower distribution volumes.
The $184 million goodwill impairment charge was linked to Cardinal's oncology practice alliance and Integrated Oncology Network, which the company acquired in late 2024. This charge was the primary driver for the 21 percent year-over-year decline in quarterly net profit.
The negative stock reaction to a guidance increase suggests investors are prioritizing top-line growth and operational health over forward-looking promises. Shareholders will watch for whether the company can reverse its revenue miss and integrate its oncology assets more effectively in its next earnings report.
This article is for informational purposes only and does not constitute investment advice.
